Friday, August 28
US immigration authorities have tightened rules on the use of photographs for immigration documents, limiting how old a photo can be and ending the acceptance of self-submitted images. The new policy, issued by the US Citizenship and Immigration Services (USCIS), takes effect immediately and is aimed at reducing identity fraud and strengthening national security. Under the updated guidance, USCIS will only use photographs that were taken within three years of the date a person files an immigration form. Photos older than three years will no longer be accepted for creating secure immigration documents. USCIS also said it will stop accepting photos submitted directly by applicants. Instead, only photographs taken by USCIS or other authorised entities will be used. USCIS said the change is de
Dear Readers, Let's end 2025 with a hypothetical tale of terrible travel luck. On your way from New York to London and Paris with your partner, someone swipes your bag from the overhead bin. The airline says sorry, but it takes no responsibility for carry-ons. You shrug it off and end up having so much fun in England that you extend your stay, skipping your flight to Paris and catching a train there a few days later. But as you're getting ready to leave Paris, you notice your return flight to New York no longer appears on the airline app. When you call, the airline says it canceled your flight after you didn't show up for the middle leg of your itinerary. So you buy new tickets, but in the stress of the situation you transpose your and your partner's middle names, and when you get to the a
Shares of Corona Remedies and Wakefit Innovations are set to debut on the stock exchanges on Monday, with grey market signals pointing to a positive start for both companies, although with different levels of investor confidence.Corona Remedies, the larger of the two in terms of market buzz, is commanding a GMP of around 28%, indicating expectations of healthy listing gains. Wakefit Innovations, in contrast, is trading at a more modest GMP of about 4%, suggesting a relatively muted debut despite its strong brand recall.Corona Remedies is coming to the market entirely through an offer for sale worth Rs 655.37 crore, with no fresh capital being raised. The issue was priced at Rs 1,062 per share and values the pharma company at a pre-IPO market cap of about Rs 6,495 crore. The shares will be
